Skip to Content Facebook Feature Image

Bybit WSOT 2026 Raises the Stakes with Anthropic (ANT)-Linked Listings and New Trading Challenges

Business

Bybit WSOT 2026 Raises the Stakes with Anthropic (ANT)-Linked Listings and New Trading Challenges
Business

Business

Bybit WSOT 2026 Raises the Stakes with Anthropic (ANT)-Linked Listings and New Trading Challenges

2026-11-20 22:16 Last Updated At:22:35

DUBAI, UAE, Nov. 20, 2026 /PRNewswire/ -- Bybit, the New Financial Platform trusted by more than 90 million registered users worldwide, is excited to announce four new Anthropic (ANT) trading tasks for the World Series of Trading (WSOT) 2026, its flagship global trading competition with up to 10 million USDT in prizes. Following Anthropic's public listing, eligible Bybit users can trade ANT through Bybit Stocks and the ANTUSDT pair on Bybit perpetual contracts to participate in WSOT 2026, earning lucky draw entries and airdrop rewards, while eligible trading volume also counts toward WSOT leaderboard rewards.

Under this year's theme, The World Trades Here, WSOT 2026 has evolved from a crypto competition into a trading tournament across asset classes. Crypto, stocks and commodities now share one account and one competition, with AI built into the full experience. The competition runs until 10:00 UTC on December 2, 2026.

Anthropic is best known for developing Claude, a family of AI models and assistants that has placed the company at center stage of the AI boom. Exposure to ANT is available to eligible Bybit users in two ways:

  1. Through Bybit Stocks, eligible users can buy and sell ANT shares, with trades settled in USDC.
  2. Through the ANTUSDT TradFi perpetual contract, eligible users can take long or short positions using a USDT-settled derivative, which provides price exposure without share ownership, voting rights or dividends.

WSOT 2026: Never Missing A Beat in Key Market Moments

To mark the historic Anthropic IPO, WSOT 2026 has introduced four new tasks for participants. The segment covers both ways to trade ANT exposure, accessible from the TradFi arena in the WSOT Preheat Quest from now until December 2, 2026.

  • Bybit Stocks and TradFi perpetual trading milestone:  Tiered trading-volume targets unlock lucky draw chances.
  • Bybit Stocks and TradFi perpetual volume challenge: An extra prize pool for users exceeding the specified volume target, limited to the first 50 eligible users for each category.

Together, the two volume challenges add an extra 50,000 USDT in airdrops to WSOT 2026. Eligible ANT trading volume also contributes to the WSOT Spot Volume and TradFi Perps leaderboards, so a single trade can count toward both task rewards and leaderboard rankings. 

Bybit Stocks debuted on October 12, 2026, and now gives eligible users access to more than 1,000 U.S.-listed stocks and ETFs through a single platform. By adding ANT to WSOT, Bybit gives its trading community more ways to access assets across crypto and TradFi, use Bybit AI and compete for rewards in one place.

Bybit Stocks - Terms and Conditions

Only users who (a) have completed Identity Verification Lv. 2 (individuals) or Business Verification Lv. 2 (entities) in accordance with the Bybit Terms of Service and Privacy Policy, and (b) have a Bybit account that remains in good standing and is in full force and effect, are eligible to use these Services.

Product availability varies by jurisdiction due to local regulatory requirements. Please refer to the Direct Stocks Product Terms for detailed service restrictions.

Disclaimer

Bybit Stocks service is provided by Infra Capital Limited (introducing broker), regulated by the Financial Services Commission, Mauritius (GB23202169). US securities clearing, settlement and custody services are provided by Alpaca Securities LLC (dba "Alpaca Clearing"), a FINRA/SIPC member. Some corporate actions may be restricted at this time. Access and ownership subject to the Bybit Stocks Terms & Conditions. Capital at risk - you may get back less than you invested. Please read the Risk Disclosures before investing.

#Bybit  / #NewFinancialPlatform 

About Bybit

Bybit is The New Financial Platform.

We believe every person should have access to every financial opportunity on earth. That's why we're building the first intelligent platform that connects anyone, anywhere to the world's finance.

Trusted by more than 90 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.

Built for everyone. Powered by intelligence. Open to the world.

Learn more at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit's Communities and Social Media

Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | YouTube

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Bybit WSOT 2026 Raises the Stakes with Anthropic (ANT)-Linked Listings and New Trading Challenges

Bybit WSOT 2026 Raises the Stakes with Anthropic (ANT)-Linked Listings and New Trading Challenges

From early antibody hits to engineered formats and antibody–oligonucleotide conjugates, Tsingke helps R&D teams generate the data they need to make the next development decision.

LISBON, Portugal, Nov. 20, 2026 /PRNewswire/ -- An antibody that binds its target is a starting point for drug discovery. R&D teams still need to determine which candidates can be produced for follow-up studies, which retain the desired binding properties in the intended format, and which merit further investment. At PEGS Europe 2026 in Lisbon, Tsingke highlighted how pharmaceutical and biotechnology teams can address these questions through an integrated workflow spanning antibody discovery, recombinant expression, engineering and characterization.

Which early antibody hits are worth advancing?

Teams starting with an immune sample or existing hybridoma clones may need to turn a list of hits into a set of recombinant antibodies they can compare. Tsingke's single B-cell screening workflow preserves native heavy- and light-chain pairing, while hybridoma sequencing gives teams a route to recover sequences from existing clones. Once candidates are expressed, teams can compare binding using assays selected for the project, such as cell-based binding by flow cytometry or binding kinetics measured by BLI or SPR. These data help teams prioritize candidates for follow-up testing.

Will the antibody retain the properties the program needs?

When a program moves an antibody into a different format, such as a Fab or scFv, the team needs to know whether the reformatted molecule still meets its binding criteria. Teams can use recombinant expression and binding characterization to compare formats before committing to more extensive studies. For programs that require different binding behavior at different pH values, Tsingke also supports pH-dependent screening and engineering, with characterization tailored to the program's objectives.

What does the team need to know before testing an antibody–oligonucleotide conjugate?

For teams evaluating an antibody–oligonucleotide conjugate (AOC), the next decision often depends on having a characterized sample for follow-up studies. Tsingke brings together antibody production, oligonucleotide synthesis, conjugation, purification and LC-MS characterization. The resulting analytical data help teams assess the conjugated material and select samples for subsequent functional evaluation.

"Teams come to us at different points in development. Some have early antibody hits and need a consistent way to compare them. Others already have a lead and need to understand how a change in format or conjugation affects the molecule they plan to test," said Yuan Wu, International BD Manager at Tsingke. "We start with the decision the team needs to make and align the production and characterization work with that decision."

About Tsingke

Beijing Tsingke Biotech Co., Ltd. provides molecular biology and biologics research services to pharmaceutical, biotechnology and academic teams. Its services include custom DNA and RNA synthesis, antibody discovery, recombinant protein production, antibody engineering and analytical characterization.

For company updates, follow Tsingke Biotech on LinkedIn.

CONTACT: market@tsingke.com.cn

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Tsingke Highlights How Biotech Teams Can Evaluate and Advance Antibody Candidates at PEGS Europe 2026

Tsingke Highlights How Biotech Teams Can Evaluate and Advance Antibody Candidates at PEGS Europe 2026

Recommended Articles